A urine based test for prostate cancer involving 18 genes PCA3 NKAIN1 B3GNT6 18 Biomarkers TFF3 SPON2 PCGEM1 TRGV9 TMSB15A ERG KLK3 KLK4 HOXC6
This test correctly identified 95% of cancer that were diagnosed as grade group 2 or higher upon biopsy.
Evaluation revealed in 99% chance that people with the negative MPS2 result did not have aggressive prostate cancer, characterized as grade group numeral 3 or higher.
The test can distinguish between high and low-grade cancers and reduces the potential harms of prostate cancer screening while preserving its long-term benefits.